议程




Co-Located Conference Agendas

Lab-on-a-Chip & Microfluidics World Congress 2019: 关于新主题、技术、运用领域的分科会“A”  |  Single Cell Analysis Summit 2019  |  Point-of-Care Diagnostics, Global Health & Biosensors 2019  |  Microfluidics & Flow Chemistry 2019  | 


2019年10月9日(三)

08:00

Morning Coffee, Pastries and Networking in the Exhibit Hall


Session Title: Emerging Trends in Single Cell Analysis (SCA), circa 2019


Venue: Coronado Ballroom 7

09:00

Keisuke GodaKeynote Presentation

Image-Activated Cell Sorting and Beyond
Keisuke Goda, Professor of Chemistry, University of Tokyo and Adjunct Professor, Wuhan University, Japan

I introduce a newly developed technology known as “Image-Activated Cell Sorting” [Cell 175, 266 (2018)] that realizes real-time image-based intelligent cell sorting at an unprecedented rate. It integrates high-throughput cell microscopy, focusing, sorting, and deep learning on a hybrid software-hardware data-management infrastructure, enabling real-time automated operation for data acquisition, data processing, intelligent decision-making, and actuation. I also show the broad utility of the technology to real-time image-activated sorting of microalgal and blood cells for studying photosynthesis and atherothrombosis, respectively. The technology is highly versatile and expected to enable machine-based scientific discovery in biological, pharmaceutical, and medical sciences.

09:30

Yu-Hwa LoKeynote Presentation

Single Cell Phenotype Analysis and Isolation based on Image-Guided Cell Sorting
Yu-Hwa Lo, Professor, University of California San Diego, United States of America

We present unique technologies that bridge single cell genomics and single cell phenotype analysis.  Tissue samples can contain millions of cells.  Even with high throughout sequencing, the NGS technologies and analysis tools may handle 1000 to 10,000 single cells for each sample due to cost and throughput considerations.  This corresponds to a very low (~0.1%) sampling ratio and increases the risk of missing important rare cells in the sample.  Currently people use cell sorting according to biomarkers to avoid the under sampling problem.  However, recent studies have shown that there exist far more cell types and degrees of heterogeneity, especially in tumorous tissues, than we have assumed before. The limited number of biomarkers and specificity of these markers have compromised our abilities to classify and sample cells in order to produce complete, unbiased understanding of the most interesting and significant cells in the population.  

To address this bottleneck, we developed high throughput flow cytometer cell sorting systems that can analyze and isolate single cells based on their phenotypic characteristics such as cell volume, shape, morphology, nuclear features, organelle distribution, speckle counts, etc.  The systems can detect both fluorescent and label-free (scattering) geometric features.  Coupled with machine learning and neural network, the systems offer capabilities to select and isolate single cells of different cell types and cell states, and to normalize the population (i.e. to select equal number of cells of the same type) to remove bias in the downstream genetic analysis.

10:00

Morning Coffee Break and Networking in the Exhibit Hall

10:30

Lydia SohnKeynote Presentation

Title to be Confirmed.
Lydia Sohn, Professor of Mechanical Engineering, University of California-Berkeley, United States of America

11:00

Precision Medicine Using Liquid Biopsies: A New Paradigm for Managing Cancer Diseases
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

Precision medicine seeks to match patients to appropriate therapies that optimize clinical outcome from molecular signatures of their disease. These molecular signatures can be secured from circulating markers found in blood (i.e., liquid biopsies). The marker types include circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). Unfortunately, many disease-associated blood markers are a vast minority in a mixed population making them difficult to analyze due to deficiencies in current technologies used for their isolation. To address this deficiency, we are generating innovative microfluidic tools for selecting circulating markers from whole blood and determining the presence/absence of disease-specific molecular signatures secured from the liquid biopsy markers to guide therapy for a patient. The microfluidics can process whole blood (=1 mL) and search for CTCs, cfDNA, or EVs and make them available for downstream molecular processing. The microfluidics are made in plastics via injection molding, making them particularly attractive for clinical implementation, which demands low-cost disposables. In this keynote address, I will discuss our microfluidic platform for cfDNA and EV isolation. The chip consists of 1.4 million pillars that provides a high surface area for generating high loads of the target material. The chip is made from a plastic via injection molding. For the EV isolation, the pillars contain surface-immobilized antibodies directed against antigens from cancer cells that are epithelial based (EpCAM) and those with a mesenchymal phenotype (fibroblast activation protein alpha, FAPa). I will talk extensively about our EV isolation chip, and its use in several clinical examples and securing molecular information from the affinity-selected exosomes, for example mRNA expression profiling using droplet digital PCR.

11:30

Molecular Machines and Industries (MMI)The Good, the Bad and the Ugly: Selective Single Cell Isolation
David Hitrys, Commercial Leader, Single-Cell Isolation, Molecular Machines and Industries (MMI)

Isolation of single cells is an essential pre-requisite for many research projects in pathology, oncology or forensics. Discussed is the development of the novel “Shake Mode” feature of the robotic-capillary system called CellEctor from MMI enabling efficient and gentle uptake of living adherent cells for many kinds of downstream analysis as well as for further cultivation.

12:00

Klaus PantelKeynote Presentation

Clinical Applications of Liquid Biopsies
Klaus Pantel, Chairman, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany

The analysis of circulating tumor cells (CTCs) and tumor cell products (DNA,RNA, extracellular vesicles) released into the blood may provide clinically relevant information as “liquid biopsy” and provide new insights into tumor biology (Pantel & Alix-Panabieres, Nature Rev Clin. Oncol. 2019). Various technologies have been developed over the past 10 years which include label-dependent assays based on the expression of tumor-associated cell surface antigens and label-independent assays based on physical properties of tumors cells distinct from the surrounding leukocytes (Pantel & Alix-Panabieres, Nature Rev Clin. Oncol. 2019). After detection CTCs can be further analyzed at the DNA, RNA and protein level to obtain global information on tumor biology and targets relevant to cancer therapy (Pantel & Alix-Panabieres, Nature Rev. Clin. Oncol. 2019). In particular, microRNAs control various genes and pathways that impact the biology of tumor cells (Anfossi, Bababayan, Pantel, Calin, Nature Rev. Clin. Oncol. 2018).

Liquid biopsy analyses with validated platforms provides reliable information on early detection of cancer, identification of cancer patients at risk to develop relapse (prognosis), and it may serve to monitor tumor evolution, identify therapeutic targets or mechanisms of resistance on metastatic cells. Metastatic cells might have unique characteristics that can differ from the bulk of cancer cells in the primary tumor currently used for stratification of patients to systemic therapy. Moreover, monitoring of blood samples before, during and after systemic therapy (e.g., chemotherapy, targeted therapy or immunotherapy (Hofman et al., Ann. Oncol. 2019)) might provide unique information for the future clinical management of the individual cancer patient and might serve as surrogate marker for response to therapy.

In conclusion, the liquid biopsy analysis can be used to improve the management of individual cancer patients and contribute to personalized medicine. CTCs are complementary to other liquid biopsy biomarkers (Alix-Panabieres & Pantel, Cancer Discovery, 2016; Bardelli & Pantel, Cancer Cell 2017). Validation of liquid biopsy assays is essential and currently performed by the EU/IMI consortium CANCER-ID (www.cancer-id.eu).

12:30

Networking Lunch in the Exhibit Hall, Exhibits and Poster Viewing

13:30

Single Vesicle Analysis to Understand Intercellular Communication
John Nolan, Professor, The Scintillon Institute, United States of America

Extracellular vesicles are released from cells carrying molecular cargo that can be transferred to other cells to affect their function. Understanding the diversity of EV released from cells is important for understanding their roles in basic biology and well as to develop EV-based biomarkers and therapeutics. A particular challenge in the field is methods to sensitively detect EVs and measure their cargo, as the small size and heterogeneity of EVs limit the usefulness of conventional biochemical analysis. Single vesicle analysis offers the possibility to understand the heterogeneity of EVs released from cells, and we have developed flow cytometry (FC)-based methods to detect and size EVs as small as ~75 nm and measure cargo to ~30 molecules per vesicle. We are using these tools to measure the number, size, and cargo of EVs released from cells and to study the roles of EVs in cell-cell communication.

14:00

Single Cell Sequencing For Predicting Chemotherapy Response in Ovarian Cancer
Timothy K. Starr, Assistant Professor, University of Minnesota, United States of America

Women with ovarian cancer suffer from high rates of recurrence and chemotherapy resistance leading to mortality. We have implemented a prospective study that incorporates single cell RNA sequencing, along with other genomic and transcriptomic analyses, to identify cellular biomarkers that predict response to chemotherapy. The ability to predict response to front-line chemotherapy would enable earlier implementation of alternative therapies when treating women with ovarian cancer.

14:30

Catherine Alix-PanabieresKeynote Presentation

Liquid Biopsy in Cancer Patients: A focus on Metastasis-Initiator Circulating Tumor Cells
Catherine Alix-Panabieres, Associate Professor, University Medical Center of Montpellier, France

Circulating tumor cells (CTCs) in blood are promising new biomarkers potentially useful for prognostic prediction and monitoring of therapies in patients with solid tumors including colon cancer. Moreover, CTC research opens a new avenue for understanding the biology of metastasis in cancer patients. However, an in-depth investigation of CTCs is hampered by the very low number of these cells, especially in the blood of colorectal cancer patients. Thus, the establishment of cell cultures and permanent cell lines from CTCs has become the most challenging task over the past year.

We described, for the first time, the establishment of cell cultures and a permanent cell line from CTCs of one colon cancer patient (Cayrefourcq et al.Cancer Res. 2015). The cell line designated CTC-MCC-41 is in culture for more than three years and has been characterized at the genome, transcriptome, proteome and secretome levels. This thorough analysis showed that CTC-MCC-41 cells resemble characteristics of the original tumor cells in the colon cancer patient and display a stable phenotype characterized by an intermediate epithelial/mesenchymal phenotype, stem-cell like properties and an osteomimetic signature indicating a bone marrow origin. Functional studies showed that CTC-MCC-41 cells induced rapidly in vitroendothelial cell tube formation and in vivotumors after xenografting in immunodeficient mice. In 2017, we defined the molecular portrait of these metastasis-competent CTCs (Alix-Panabieres et al. Clin Chem. 2017). These results highlight that CTC-MCC-41 line display a very specific transcription program completely different than those of the primary and metastatic colon cancer cell lines.More recently, we characterized 8 additional CTC lines using blood samples from the same metastatic cancer: a unique biological material collected before and after chemotherapy and targeted therapy, and during cancer progression (Soler et al. Sci. Rep. 2018).

Such data may supply insights for the discovery of new biomarkers to identify the most aggressive CTC sub-populations and for the development of new drugs to inhibit metastasis-initiator CTCs in colon cancer.

15:00

Cancer-Associated Subclones Among Mesenchymal Stem Cells Revealed by Single-Cell Transcriptome Analyses
Jiang Zhong, Assistant Professor, University of Southern California, United States of America

Despite the clinical benefits, detrimental effects of mesenchymal stem cells (MSCs) in clinical reports have been reported, in some cases fomenting tumorigenicity. Some of MSC subpopulations may be responsible for variation in the efficacy of bone marrow transplantation (BMT) and MSC-based therapy as well as tumorigenicity. Such heterogeneity of MSCs was not fully addressed until the arrival of the single-cell transcriptome technology. Recently, we report three discrete stages of osteogenesis based on a single-cell transcriptome analysis of individual MSCs during osteocyte differentiation. We identified a subpopulation of osteogenesis-resistant MSCs that have cancer stem cell characteristics. Further analysis indicated that the YAP1, β-Catenin and Cadherin4/6 pathways involved in osteogenesis-resistance. Clinical surveys using 51 clinical databases across 6,965 patients revealed a correlation between YAP1/ β-Catenin/Cadherin4/6 over-expression and cancer progression. This study suggested that a differentiation-resistant population of MSC with cancer stem cell characteristics is responsible for the tumorigenicity of MSC. Therefore, intervention of the YAP1, β-Catenin and Cadherin4/6 pathway could potentially prevent tumorgenicity in MSC therapies by addressing the preexisting subpopulation of MSCs namely those differentiation-resistant populations associated with active YAP1-Cadherin pathway. Biologically active molecules targeting YAP1/ β-Catenin/Cadherin could improve MSC therapy for a defined subset of patients by minimizing the tumorgenicity of MSCs.

15:30

Afternoon Coffee Break

16:00

Click Chip Enables Non-Invasive mRNA Analysis in Circulating Tumor Cells
Yazhen Zhu, Assistant Project Scientist, David Geffen School of Medicine at UCLA, United States of America

Recent research focus in the field of circulating tumor cells (CTCs) has moved beyond the simple capture or enumeration of CTCs and gravitated towards approaches that allow for in-depth molecular analysis. CTCs house intact mRNA, providing more reliable gene signatures in tumors non-invasively. Exploring the use of CTC-derived mRNA offers a non-invasive diagnostic solution for understanding underlying tumor biology, guiding treatment intervention, and monitoring disease progression. Recently, we demonstrated a new covalent chemistry-enabled CTC capture/release platform - “Click Chip”. This platform is designed by integrating bioorthogonal ligation-mediated CTC capture (sensitive and rapid) and disulfide cleavage-driven CTC release (mild, specific, and rapid) on nanostructured substrates to enable efficient purification of CTCs with high-quality CTC-derived mRNA. The CTC-derived mRNA was subjected to RT-droplet digital PCR (RT-ddPCR) or Nanostring nCounter platform. In our proof of concept study, ALK/ROS1 rearrangements were quantified using CTC-mRNA recovered by Click Chips and matched with those identified in biopsy specimen in late-stage ALK/ROS1 positive NSCLC patients. Further, CTC-mRNA recovered from HCC patients by Click Chips can be used for HCC-specific mRNA profiling for predicting HCC prognosis. This streamlined workflow is optimum for non-invasive gene expression profiling based on high-quality CTC-derived mRNA.

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English



免费电子邮件通知服务